Skip to content

All recalls FDA

FDADrugsRecalled Status: Ongoing

Cipla USA, Inc. recalls Lanreotide Injection

Class IIofficial

FDA Class II

FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.

Hazard
Presence of Particulate Matter.
Products
  • Lanreotide Injection
Where it was sold

Nationwide in the USA

Nationwide

Units affected
15,221 syringes
About this recall
Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67